BSE Live
Mar 24, 16:01Prev. Close
1559.15
Open Price
1573.60
Bid Price (Qty.)
1575.10 (10)
Offer Price (Qty.)
1587.25 (8)
NSE Live
Mar 24, 15:57Prev. Close
1560.30
Open Price
1604.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1586.30 (83)
| Cash Flow of Caplin Point Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 9 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 253.12 | 202.65 | 146.05 | 92.58 | 58.38 | |
| Net CashFlow From Operating Activities | 87.01 | 107.34 | 22.61 | 55.49 | 44.37 | |
| Net Cash Used In Investing Activities | -41.06 | -76.51 | -59.71 | -37.07 | -5.98 | |
| Net Cash Used From Financing Activities | -32.92 | -15.21 | -11.60 | -6.74 | -13.95 | |
| Foreign Exchange Gains / Losses | 0.05 | 0.72 | -0.01 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 13.09 | 16.34 | -48.71 | 11.67 | 24.45 | |
| Cash And Cash Equivalents Begin of Year | 42.52 | 26.18 | 74.89 | 63.22 | 40.32 | |
| Cash And Cash Equivalents End Of Year | 55.61 | 42.52 | 26.18 | 74.89 | 64.77 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
25.03.2026
25.03.2026
24.03.2026
24.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth